XML 66 R4.htm IDEA: XBRL DOCUMENT v2.4.0.8
CONSOLIDATED STATEMENTS OF OPERATIONS (USD $)
In Thousands, except Share data, unless otherwise specified
 12 Months Ended
Dec. 31, 2013
Dec. 31, 2012
Dec. 31, 2011
Revenues:      
Royalties $ 23,584 $ 14,073 $ 9,213
Material Sales 19,072 9,432 12,123
Collaborative research and development and other revenues 6,317 7,883 8,701
Total revenues 48,973 31,388 30,037
Operating costs and expenses:      
Cost of material sales 5,732 3,601 4,909
Research and development 9,274 10,790 10,291
General and administrative 17,984 15,782 14,583
Lease exit and termination costs 560 1,022 552
Write-off of acquired in-process research and development 480 0 2,282
Total operating costs and expenses 34,030 31,195 32,617
Accretion of deferred gain on sale leaseback 0 0 1,702
Income (loss) from operations 14,943 193 (878)
Other (expense) income:      
Interest expense, net (2,077) (2,924) (2,297)
Increase in contingent liabilities (3,597) (1,650) (1,013)
Other, net (63) 516 630
Total other expense, net (5,737) (4,058) (2,680)
Income (loss) from continuing operations before income tax benefit 9,206 (3,865) (3,558)
Income tax (expense) benefit from continuing operations (374) 1,191 13,270
Income (loss) from continuing operations 8,832 (2,674) 9,712
Discontinued operations:      
Gain on sale of Product Line, net 2,588 3,656  
Income tax expense on discontinued operations    (1,509) 0
Income from discontinued operations 2,588 2,147 3
Net income (loss) 11,420 (527) 9,715
Basic per share amounts:      
Income (loss) from continuing operations (in usd per share) $ 0.43 $ (0.14) $ 0.49
Income from discontinued operations (in usd per share) $ 0.13 $ 0.11 $ 0.00
Net income (loss) (in usd per share) $ 0.56 $ (0.03) $ 0.49
Weighted average number of common shares-basic (in shares) 20,312,395 19,853,095 19,655,632
Diluted per share amounts:      
Income (loss) from continuing operations (in usd per share) $ 0.43 $ (0.14) $ 0.49
Income from discontinued operations (in usd per share) $ 0.12 $ 0.11 $ 0.00
Net income (loss) income (in usd per share) $ 0.55 $ (0.03) $ 0.49
Weighted average number of common shares-diluted (in shares) 20,745,454 19,853,095 19,713,320
AVINZA Product Line
      
Discontinued operations:      
Gain on sale of Product Line, net 2,588 3,656 0
Oncology Product Line
      
Discontinued operations:      
Gain on sale of Product Line, net $ 0 $ 0 $ 3